Comparison · NCT02858076-3e60c19a
Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Recurrent Vitreous Hemorrhage
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: Recurrent Vitreous Hemorrhage. Trial comparisons, record NCT02858076-3e60c19a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02858076-3e60c19a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.495 | 0.397 | 0.593 | wilson | |
| Risk in group 2 | 0.154 | 0.097 | 0.235 | wilson | |
| Risk difference, group 1 minus group 2 | 0.341 | 0.214 | 0.454 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.22 | 1.96 | 5.27 | log | |
| Odds ratio, group 1 over group 2 | 5.39 | 2.77 | 10.5 | log | |
| Number needed to treat, for one more participant with the outcome on Intravitreous 2 mg Aflibercept Injections than on Prompt Vitrectomy Plus Panretinal Photocoagulation | 2.93 | 2.2 | 4.67 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intravitreous 2 mg Aflibercept Injections | Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.~2-mg Intravitreous Aflibercept Injection: Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor. | 48 | 97 | OG000 |
| Group 2 | Prompt Vitrectomy Plus Panretinal Photocoagulation | For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.~Prompt Vitrectomy Plus Panretinal Photocoagulation: Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser | 16 | 104 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Recurrent Vitreous Hemorrhage
- Description
- Assessed by the investigator and defined as presence of vitreous hemorrhage after a period of absence. Excludes eyes in which vitreous hemorrhage could not be assessed during follow-up.
- Time frame
- At any time through 2 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
- NCT number
- NCT02858076
- Phases
- PHASE2, PHASE3
- Conditions
- Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
- Interventions
- 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
- Lead sponsor
- Jaeb Center for Health Research
- Results first posted
- 2021-01-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02858076?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02858076-3e60c19a